Topical Rapamycin for Angiofibromas in Patients With Tuberous Sclerosis: How Does It Work in Clinical Practice?

Plastic and Aesthetic Research
doi 10.20517/2347-9264.2016.60
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OAE Publishing Inc.

Related search

Topical Rapamycin for Facial Angiofibromas in a Child With Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-Up

Dermatology and Therapy
Dermatology
2017English

Successful Treatment of Subungual Fibromas of Tuberous Sclerosis With Topical Rapamycin

JAMA Dermatology
DermatologyMedicine
2014English

Efficacy of Rapamycin in Tuberous Sclerosis–Associated Hypopigmented Macules

JAMA Dermatology
DermatologyMedicine
2015English

Retraction: Mammalian Target of Rapamycin Inhibitors for Treatment in Tuberous Sclerosis

Korean Journal of Pediatrics
Child HealthPediatricsPerinatology
2013English

How Long Does It Take to Assess Literacy Skills in Clinical Practice?

Journal of the American Board of Family Medicine
EnvironmentalPublic HealthFamily PracticeOccupational Health
2008English

Carotid Endarterectomy: How Does It Work? A Clinical and Angiographic Evaluation

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
1986English

Rapamycin Prevents Epilepsy in a Mouse Model of Tuberous Sclerosis Complex

Annals of Neurology
Neurology
2008English

Cytopostgenomics: What Is It and How Does It Work?

Current Genomics
Genetics
2019English

Topographical Distribution of Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex

Journal of Child Neurology
Child HealthNeurologyPediatricsPerinatology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy